AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages

January 29, 2009

MINNEAPOLIS, Jan. 29 /PRNewswire/ — AGA Medical Corporation (AGA) today
announced that, following its previously announced favorable patent
infringement final ruling by the German court of appeals over Occlutech GmbH
of Jena, Germany (Occlutech), it has calculated and notified Occlutech of the
amount of damages that it will seek from Occlutech based on the court’s
ruling. After learning that Occlutech has terminated all manufacturing and
sales and that its CEO has resigned, AGA has started proceedings in the
insolvency court in Germany to protect AGA’s claims for damages.

The lawsuit was brought by AGA in 2006 in Dusseldorf, Germany, seeking to
enjoin Occlutech from infringing the German part of AGA’s European patent (EP
0 808 138) and for damages resulting therefrom. The final ruling in favor of
AGA from the German court of appeals was announced on January 6.

About AGA Medical Corporation

AGA Medical Corporation, based in Plymouth, Minnesota, is a leader in
developing interventional devices for the minimally invasive treatment of
cardiovascular defects and peripheral vascular disease. Founded in 1995 by Dr.

Kurt Amplatz, a former professor and researcher at the University of Minnesota
Department of Radiology, AGA develops and commercializes devices for a range
of structural heart repair and circulatory conditions. Several of these
devices have been major innovations in the treatment of the most common
congenital “holes in the heart”, such as atrial septal defects and patent
foramen ovales.

More than 700 articles have been published in medical literature that
support the benefits of AGA devices, including improved patient outcomes,
reduced length of stay, and accelerated recovery times for the patient. AGA
devices have received regulatory approval and are marketed in 101 countries.
For more information, visit http://www.amplatzer.com.

SOURCE AGA Medical Corporation

Source: newswire

comments powered by Disqus